Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 361 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR ESMO Clinical Practice Guideline Express Update on the adoption of physical... January 27, 2026 The US National COVID Cohort Collaborative Consortium Provides Real-World Evidence on... March 29, 2022 FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple... August 8, 2025 FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour November 26, 2021 Load more HOT NEWS Spotlight On: Pelvic Physical Therapists in Cancer Care Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... Bride Diagnosed with Stage IV Triple-Negative Breast Cancer 6 Months Before... Hospice Nurse Fired from Job After Being Diagnosed with Breast Cancer
